Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

To access The New England Journal of Medicine publication on the Phase 3 ANNEXA studies of andexanet alfa visit: http://www.nejm.org/doi/full/10.1056/NEJMoa1510991

Media Kit
 Portola Pharmaceuticals Fact Sheet
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
There are no past events to display.
Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$29.52
Change (%) Stock is Up 0.56 (1.93%)
Volume154,815
Data as of 02/12/16 10:33 a.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 130 employees.<... More >>

Recent NewsMore >>
DateTitle 
02/01/16Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 Million
Portola Retains Full Worldwide Commercial Rights to Andexanet Alfa Outside of Japan SOUTH SAN FRANCISCO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (NASDAQ:PTLA), announced today that it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to Bristol-Myers Squibb Company and Pfizer Inc. to be developed as an antidote for apixaban and other Factor Xa inhibitors. Separately, Portola has entered into a clinical collaborat... 
Printer Friendly Version
01/08/16Portola Pharmaceuticals to Webcast Corporate Update on January 12, 2016
Two Products in Thrombosis Franchise Expected to Launch in Next 18 Months SOUTH SAN FRANCISCO, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host an investor webcast to review its recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 12, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 34th Annual J.P. Morgan Healthcare Conference in... 
Printer Friendly Version
12/18/15Portola Pharmaceuticals Completes BLA Submission to U.S. Food and Drug Administration for Andexanet Alfa
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today completion of the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational agent andexanet alfa, an FDA-designated breakthrough therapy specifically designed to reverse the anticoagulant activity of both direct and indirect Factor Xa inhibitors. Portola is developing andexanet alfa as a universal reversal ag... 
Printer Friendly Version
12/05/15Portola Pharmaceuticals Announces Andexanet Alfa and Cerdulatinib Data Presentations at the 2015 American Society of Hematology Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the presentation of new results from clinical and non-clinical studies of two of its investigational pipeline products – the Factor Xa inhibitor reversal agent andexanet alfa and the oral, dual Syk/JAK kinase inhibitor cerdulatinib – at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. Andexanet alfa, a U.S. Food and Drug Administrat... 
Printer Friendly Version
12/04/15Portola Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today the pricing of its underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $48.00 per share.  In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 468,750 shares from Portola at the public offering price. The offering is expected to close on December 9, 2015, subject to cust... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.